Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.050
-0.030 (-1.44%)
At close: Sep 17, 2025, 4:00 PM EDT
2.040
-0.010 (-0.49%)
After-hours: Sep 17, 2025, 7:53 PM EDT
Innate Pharma Revenue
Innate Pharma had revenue of 7.78M EUR in the half year ending December 31, 2024, a decrease of -35.66%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.
Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
12.97
Revenue / Employee
69,812 EUR
Employees
181
Market Cap
192.44M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.12M | -41.52M | -67.36% |
Dec 31, 2023 | 61.64M | 3.97M | 6.88% |
Dec 31, 2022 | 57.67M | 32.97M | 133.47% |
Dec 31, 2021 | 24.70M | -45.07M | -64.60% |
Dec 31, 2020 | 69.77M | -15.68M | -18.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IPHA News
- 13 hours ago - Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Innate Pharma Reports First Half 2025 Business Update and Financial Results - Business Wire
- 3 days ago - Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event - Business Wire
- 7 days ago - Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update - Business Wire
- 7 weeks ago - Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference - Business Wire
- 3 months ago - Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences - Business Wire
- 3 months ago - Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 4 months ago - Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences - Business Wire